Cemiplimab + Fianlimab + Ipilimumab for Melanoma

This trial examines the safety and initial effectiveness of combining three immunotherapy drugs—cemiplimab, fianlimab, and ipilimumab—to treat certain types of melanoma, a serious skin cancer. It targets individuals who have not received prior treatment for melanoma, specifically those with stage III or some surgically removable stage IV types. This trial may suit individuals with noticeable melanoma that can be fully removed by surgery. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive drugs or certain other treatments, you might need to stop them before joining the trial. It's best to discuss your specific medications with the trial team.

Research has shown that combining cemiplimab, fianlimab, and ipilimumab may help treat melanoma. However, earlier studies reported that nearly 44% of patients experienced severe side effects, classified as grade 3 or higher adverse events. Serious side effects occurred in about 33% of patients. Some patients also faced immune-related problems, where the immune system mistakenly attacked healthy cells.

Researchers are excited about combining Cemiplimab, Fianlimab, and Ipilimumab for treating melanoma because this trio targets the immune system in a unique way. While most current treatments focus on blocking a single checkpoint, this combination harnesses the power of three different immune checkpoint inhibitors. Cemiplimab and Ipilimumab are known to block PD-1 and CTLA-4 pathways, respectively, while Fianlimab adds a novel twist by targeting LAG-3, another immune checkpoint. By attacking the cancer from multiple angles, this approach has the potential to enhance the immune response against melanoma more effectively than standard treatments.

Studies have shown that combining cemiplimab and fianlimab can effectively treat advanced melanoma, a type of skin cancer. Earlier research demonstrated that this combination helped shrink or halt the cancer in 61% of patients. In this trial, participants will receive cemiplimab, fianlimab, and ipilimumab. Adding ipilimumab may enhance the treatment, as it aids the immune system in fighting cancer. Although still in the early stages, these findings suggest that this three-drug combination could significantly benefit people with melanoma.¹²⁴⁵⁶